Proactive Investors - Run By Investors For Investors

Satu Vainikka, from Valirx, talks about the unlimited potential of GeneICE

Dr Satu Vainikka, CEO at Valirx (LON:VAL), tells Proactive Investors that there is tremendous potential for its GeneICE programme Satu believes that the recently raised £3.3mln will see Valirx through to pre-clinical studies at which point it is likely that a commercial joint venture partner will be found within the sector.
 
Meet Faron Pharmaceuticals Ltd, Belvoir Lettings, Silence Therapeutics PLC, ANGLE PLC and ReNeuron Group PLC at our event, London , 23 May 2019. Register here »
View full VAL profile View Profile

ValiRx Plc Timeline

Big Picture
May 02 2019

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use